Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, May 17, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), perioperative treatment with nivolumab results in significantly longer event-free survival, according to a study published in the May 16/23 issue of the New England Journal of Medicine.
Tina Cascone, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a phase 3, randomized trial involving adults with resectable stage IIA to IIIB NSCLC. Participants were randomly assigned to receive neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo every three weeks for four cycles, followed by surgery and adjuvant nivolumab or placebo every four weeks for one year.
The researchers found that the percentage of patients with 18-month event-free survival was 70.2 and 50.0 percent in the nivolumab and chemotherapy groups, respectively, at the prespecified interim analysis (median follow-up, 25.4 months; hazard ratio for disease progression or recurrence, abandoned surgery, or death, 0.58). A pathological complete response occurred in 25.3 and 4.7 percent of patients in the nivolumab and chemotherapy groups, respectively (odds ratio, 6.64); a major pathological response occurred in 35.4 and 12.1 percent, respectively (odds ratio, 4.01). Grade 3 or 4 treatment-related adverse events occurred in 32.5 and 25.2 percent of those in the nivolumab and chemotherapy groups, respectively.
"We found that the addition of perioperative nivolumab to neoadjuvant chemotherapy resulted in significantly longer event-free survival than perioperative placebo added to neoadjuvant chemotherapy in patients with resectable NSCLC," the authors write.
The study was funded by Bristol Myers Squibb, the manufacturer of nivolumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
THURSDAY, June 6, 2024 -- For patients with non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant, ivonescimab plus chemotherapy improves...
ASCO: Osimertinib Improves Progression-Free Survival in EGFR-Mutated Lung Cancer
WEDNESDAY, June 5, 2024 -- For patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC), treatment with osimertinib results in significantly longer...
ASCO: Stepped-Care Model Noninferior to Early Palliative Care for Advanced Cancer
TUESDAY, June 4, 2024 -- For patients with advanced lung cancer, a stepped-care model with palliative care visits occurring at key points in patients' cancer trajectory is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.